Abstract
Abstract
The use of prostaglandin E1 is well documented in ductus arteriosus-dependent CHD or in neonatal pulmonary pathologies that cause severe pulmonary hypertension. The intravenous infusion is well established in loading infusion and maintenance with an onset of action of 30 minutes until 2 hours or even more. Our aim is to report three patients with pulmonary atresia that presented hypercyanotic spell due to a ductal spasm during cardiac catheterisation in whom the administration of a bolus of alprostadil reversed the spasm and increased pulmonary flow, immediately stabilising the condition of the patients allowing subsequent successful stent placement with no serious complications or sequelae after the administration of the bolus. More studies are needed to make a recommendation regarding the use of alprostadil in bolus in cases where the ductal spasm might jeopardise the life of the patient.
Publisher
Cambridge University Press (CUP)
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Pediatrics, Perinatology and Child Health
Reference7 articles.
1. The Isolation of Prostaglandin.
2. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit;Dice;J Pediatr Pharmacol Ther,2006
3. The prostaglandins. A family of biologically-active lipids;Bergström;Pharmacol Rev,1948
4. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease.
5. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease.